Pathological Response and Nodal Status Guide Adjuvant Immunotherapy in NSCLC After Neoadjuvant Chemoimmunotherapy: An Eastern Asian Cohort Study - PubMed
4 hours ago
- #chemoimmunotherapy
- #adjuvant therapy
- #lung cancer
- The study focuses on the role of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC).
- A risk stratification model was developed based on pathological response (MPR) and nodal status (ypN) to identify patients who benefit most from adjuvant immunotherapy.
- The study included 363 patients with resectable NSCLC (stage IB-III) who underwent neoadjuvant chemoimmunotherapy followed by surgery.
- Adjuvant immunotherapy showed no survival benefit in the overall cohort but was beneficial for the non-MPR ypN+ group, improving recurrence-free and overall survival.
- No survival benefit was observed in patients achieving MPR or nodal clearance (MPR ypN0, non-MPR ypN0, or MPR ypN+ groups).
- The MPR-ypN classification helps in selectively administering adjuvant immunotherapy to those likely to benefit, avoiding unnecessary treatment for others.